This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fischer, W. Articles by Svanborg, C. Search for Related Content PubMed PubMed Citation Articles by Fischer, W. Articles by Svanborg, C.

Human -Lactalbumin Made Lethal to Tumor Cells (HAMLET) Kills Human Glioblastoma Cells in Brain Xenografts by an Apoptosis-Like Mechanism and Prolongs Survival

¹ Institute of Laboratory Medicine, Department of Microbiology, Immunology and Glycobiology, University of Lund, Sweden; ² Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway; ³ Department of Physiology, University of Bergen, Bergen, Norway; ⁴ Department of Pathology, Haukeland University Hospital, Bergen, Norway; and ⁵ NorLux Neuro-Oncology, Department of Biomedicine, University of Bergen and Centre de Reserche Public de la Santé Luxembourg, Bergen, Norway

Malignant brain tumors present a major therapeutic challenge because no selective or efficient treatment is available. Here, we demonstrate that intratumoral administration of human -lactalbumin made lethal to tumor cells (HAMLET) prolongs survival in a human glioblastoma (GBM) xenograft model, by selective induction of tumor cell apoptosis. HAMLET is a protein-lipid complex that is formed from -lactalbumin when the protein changes its tertiary conformation and binds oleic acid as a cofactor. HAMLET induces apoptosis in a wide range of tumor cells in vitro, but the therapeutic effect in vivo has not been examined. In this study, invasively growing human GBM tumors were established in nude rats (Han:rnu/rnu Rowett, n = 20) by transplantation of human GBM biopsy spheroids. After 7 days, HAMLET was administered by intracerebral convection-enhanced delivery for 24 h into the tumor area; and -lactalbumin, the native, folded variant of the same protein, was used as a control. HAMLET reduced the intracranial tumor volume and delayed the onset of pressure symptoms in the tumor-bearing rats. After 8 weeks, all -lactalbumin-treated rats had developed pressure symptoms, but the HAMLET-treated rats remained asymptomatic. Magnetic resonance imaging scans revealed large differences in tumor volume (456 versus 63 mm³). HAMLET caused apoptosis in vivo in the tumor but not in adjacent intact brain tissue or in nontransformed human astrocytes, and no toxic side effects were observed. The results identify HAMLET as a new candidate in cancer therapy and suggest that HAMLET should be additionally explored as a novel approach to controlling GBM progression.

This article has been cited by other articles:

				S. M. Rough, P. Sakamoto, C. H. Fee, and C. B. Hollenbeck Qualitative Analysis of Cancer Patients' Experiences Using Donated Human Milk J Hum Lact, May 1, 2009; 25(2): 211 - 219. [Abstract] [PDF]

				P. Brest, M. Gustafsson, A.-K. Mossberg, L. Gustafsson, C. Duringer, A. Hamiche, and C. Svanborg Histone Deacetylase Inhibitors Promote the Tumoricidal Effect of HAMLET Cancer Res., December 1, 2007; 67(23): 11327 - 11334. [Abstract] [Full Text] [PDF]

				L. Gustafsson, O. Hallgren, A.-K. Mossberg, J. Pettersson, W. Fischer, A. Aronsson, and C. Svanborg HAMLET Kills Tumor Cells by Apoptosis: Structure, Cellular Mechanisms, and Therapy J. Nutr., May 1, 2005; 135(5): 1299 - 1303. [Abstract] [Full Text] [PDF]

				L. Gustafsson, I. Leijonhufvud, A. Aronsson, A.-K. Mossberg, and C. Svanborg Treatment of Skin Papillomas with Topical {alpha}-Lactalbumin-Oleic Acid N. Engl. J. Med., June 24, 2004; 350(26): 2663 - 2672. [Abstract] [Full Text] [PDF]